Ascendo Biotechnology is pleased to announce that the company has received The 22nd National Innovation Award, recognizing its innovation and translational progress in immune-based therapeutics.
The award specifically acknowledges Ascendo’s proprietary technology platform, “Pioneering Innate Immunity: First-In-Class CD11b Modulation for Cancer and Autoimmunity,” which represents a novel approach to targeting innate immune pathways for the treatment of cancer and autoimmune diseases. By selectively modulating CD11b, this first-in-class platform is designed to reshape immune responses and address critical unmet medical needs across multiple indications.
Ascendo will continue to advance its CD11b modulation platform and pipeline development, with a focus on clinical translation, strategic partnerships, and global development opportunities.
先知生物科技榮獲 第22屆國家新創獎—企業新創獎，此項殊榮肯定本公司在創新免疫療法研發與技術轉譯上的成果與產業價值。
本次獲獎特別表彰先知生物科技的核心技術平台——「全球首創 CD11b 調控平台：打造癌症與自體免疫疾病的先天免疫治療新策略」。此平台以先天免疫為切入點，透過 CD11b 的精準調控，建立具差異化與首創性的治療策略，回應癌症與自體免疫疾病領域長期存在的未滿足醫療需求。
先知生物科技將持續推進 CD11b 調控平台及相關產品開發，聚焦臨床轉譯、策略合作與國際布局，加速創新免疫療法的全球發展。
(中)先知生物科技科學長暨 CD11b 調控平台發明人 呂衍達博士